Time Magazine 50 Best Inventions of 2010 for Engineered Lung, 2010.
Photo by Jamie Chung for Time
Petersen, T.H., Calle, E.A., Zhao, L., Lee, E.J., Gui, L., Raredon, M.B., Gavrilov, K., Yi, T., Zhuang, Z.W., Breuer, C., Herzog, E., and Niklason, L.E. Tissue-Engineered Lungs for in Vivo Implantation. Science. 329(5991): 538-41, 2010.
Department of Anesthesiology under the strong visionary leadership of Dr. Hines has risen from a ranking of 20 to 10 in NIH funding (Blue Ridge Institute) with an approximate total annual Federal and non-federal funding of $6.0M/Yr in 2017-2018. Our strategy has been, and will continue to be, to build an interdisciplinary research team of recognized and emerging scientists who work together to produce new knowledge and develop the next generation of physician-scientists in Anesthesiology and Perioperative Medicine.
The growth of the interdisciplinary research endeavor within the Department has been structured around three broad research priorities: Cardiovascular Biology, Neuroscience and integrative imaging, and the development of a robust translational arm focused on Clinical Trials. Our interdisciplinary approach further provides for new areas of study, many of which emerge from overlap between these themes. The Cardiovascular Biology program has a strong footprint across Yale campus with research spanning from basic to translational to clinical, and includes patient physiology, cell biology, and cell therapy. The Neuroscience and Clinical Trials themes have grown rapidly over the past several years. The expansion of our clinical trials portfolio has allowed us to test and offer new therapies and approaches to clinical anesthesia, with a focus on Enhanced Recovery after Surgery and long-term post-surgical outcomes. Our expanding focus in Neurobiology has resulting in the training of several new young faculty members in basic neuroscience fields, as well as the recruitment of a senior Neurobiologist with a focus on imaging, opioid addiction, and glymphatic pathways.
Projected Future Growth:
Having established this tripartite structure over the past 3-4 years, the next steps are to leverage our existing expertise, to identify and pursue areas of synergy that both expand
knowledge and address the public health needs of society. These opportunities for future growth of the research mission will include, but certainly are not limited to, the following areas:
• Opioid pharmacology and opioid addiction
• Expansion of ground-breaking research on the brain waste glymphatic pathway
• Novel clinical care pathways, including in the ICU, OR anesthesia, and pain
• Expanding our sponsored clinical research portfolio
• Micro-vascular pathophysiology and pharmacology
• Growth in Regenerative Medicine therapies